NO990003D0 - Administreringssystem for genterapi - Google Patents

Administreringssystem for genterapi

Info

Publication number
NO990003D0
NO990003D0 NO990003A NO990003A NO990003D0 NO 990003 D0 NO990003 D0 NO 990003D0 NO 990003 A NO990003 A NO 990003A NO 990003 A NO990003 A NO 990003A NO 990003 D0 NO990003 D0 NO 990003D0
Authority
NO
Norway
Prior art keywords
management system
gene therapy
therapy management
dna
positively charged
Prior art date
Application number
NO990003A
Other languages
English (en)
Norwegian (no)
Other versions
NO990003L (no
Inventor
Lisbeth Illum
Original Assignee
Danbiosyst Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614471.2A external-priority patent/GB9614471D0/en
Priority claimed from GBGB9614441.5A external-priority patent/GB9614441D0/en
Application filed by Danbiosyst Uk Ltd filed Critical Danbiosyst Uk Ltd
Publication of NO990003D0 publication Critical patent/NO990003D0/no
Publication of NO990003L publication Critical patent/NO990003L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Saccharide Compounds (AREA)
NO990003A 1996-07-10 1999-01-04 Administreringssystem for genterapi NO990003L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9614471.2A GB9614471D0 (en) 1996-07-10 1996-07-10 Gene delivery to epithelial cells
GBGB9614441.5A GB9614441D0 (en) 1996-07-10 1996-07-10 Gene therapy delivery system for targeting to the lung endothelia
PCT/GB1997/001860 WO1998001161A2 (fr) 1996-07-10 1997-07-10 Systeme d'administration d'une therapie genique ciblee sur l'endothelium

Publications (2)

Publication Number Publication Date
NO990003D0 true NO990003D0 (no) 1999-01-04
NO990003L NO990003L (no) 1999-01-04

Family

ID=26309674

Family Applications (2)

Application Number Title Priority Date Filing Date
NO990002A NO990002L (no) 1996-07-10 1999-01-04 Blandinger for administrasjon av gener
NO990003A NO990003L (no) 1996-07-10 1999-01-04 Administreringssystem for genterapi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO990002A NO990002L (no) 1996-07-10 1999-01-04 Blandinger for administrasjon av gener

Country Status (13)

Country Link
EP (2) EP0994726B1 (fr)
JP (2) JP2000514086A (fr)
KR (2) KR20000067855A (fr)
AT (2) ATE216264T1 (fr)
AU (2) AU726518C (fr)
CA (2) CA2257408A1 (fr)
DE (2) DE69712108T2 (fr)
DK (1) DK0986404T3 (fr)
ES (2) ES2175434T3 (fr)
GB (2) GB2330534B (fr)
NO (2) NO990002L (fr)
PT (2) PT986404E (fr)
WO (2) WO1998001161A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
JPH11246392A (ja) * 1998-03-03 1999-09-14 Makoto Otsuka 経口用固形製剤
WO1999058656A2 (fr) * 1998-05-13 1999-11-18 The Regents Of The University Of Michigan Liberation prolongee d'adn depuis des matrices structurales
JP4360758B2 (ja) 1999-04-08 2009-11-11 ジェネンテック・インコーポレーテッド 逆の電荷のポリペプチド類をベースにした組成物
DE19940795A1 (de) * 1999-08-27 2001-03-01 Lohmann Therapie Syst Lts Schnellzerfallende Pellets auf der Basis von Chitosan
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
ES2230784T3 (es) * 1999-11-18 2005-05-01 Cognis Iberia, S.L. Microcapsulas.
FR2801811B1 (fr) * 1999-12-06 2002-05-03 Gerard Habar Procede de fabrication de microcapsules portant des charges cationiques
ES2525087T5 (es) 2000-05-10 2018-06-28 Novartis Ag Polvos basados en fosfolípidos para administración de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001287375B2 (en) * 2000-09-14 2005-12-15 Px Biosolutions Pty Ltd Composition comprising immunogenic microparticles
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
CN1543338B (zh) 2001-08-16 2010-06-16 Cmp医疗有限公司 壳多糖微粒及其医疗用途
WO2003028657A2 (fr) * 2001-10-03 2003-04-10 The Johns Hopkins University Compositions pour therapie genique orale et procedes d'utilisation associes
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
NO317653B1 (no) 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav.
AU2003253508A1 (en) * 2002-07-15 2004-02-02 Feyecon Development And Implementation B.V. Method for particle precipitation using near-critical and supercritical antisolvents
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040048260A1 (en) * 2002-09-10 2004-03-11 Fu-Hsiung Chang Transfection of nucleic acid
US20040133099A1 (en) * 2002-12-18 2004-07-08 Dyer R. Kent Otologic nanotechnology
US8651113B2 (en) 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
US7723311B2 (en) 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
DE10329087B4 (de) 2003-06-27 2014-02-13 Biomedical International R + D Gmbh Antigenhaltige Mikrosphären zur Allergietherapie
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
JP4674288B2 (ja) * 2004-03-31 2011-04-20 恵雄 岡畑 歯科用材料。
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
AU2007285472B2 (en) * 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
EP2007358A4 (fr) * 2006-04-04 2012-01-25 Stc Unm Particules gonflantes pour l'administration d'un médicament
CA2729923A1 (fr) * 2007-07-06 2009-01-15 Aarhus Universitet Nanoparticules deshydratees de chitosane
RU2010116775A (ru) * 2007-09-28 2011-11-10 Энджин, Инк. (Ca) Высококонцентрированные композиции полиплекса хитозана и нуклеиновой кислоты
JP5841708B2 (ja) * 2008-07-01 2016-01-13 日東電工株式会社 表面被覆微粒子の医薬組成物
CN101869704A (zh) * 2010-06-08 2010-10-27 中国药科大学 单剂免疫破伤风类毒素阳离子葡聚糖微球及其制备方法
US8802076B2 (en) 2010-10-04 2014-08-12 Duke University Compositions and methods for modulating an immune response
EP4093437A4 (fr) * 2020-01-22 2024-07-17 Engene, Inc. Expression localisée d'acides nucléiques thérapeutiques dans des cellules épithéliales pulmonaires

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046750A (en) * 1974-09-30 1977-09-06 California Institute Of Technology Ionene modified small polymeric beads
JPH03198782A (ja) * 1989-12-27 1991-08-29 Bitamin Kenkyusho:Kk 遺伝子導入用キャリアー、該キャリアーと遺伝子との複合体及び細胞への遺伝子導入法
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
AU2946295A (en) * 1994-06-27 1996-01-19 Johns Hopkins University, The Targeted gene delivery system
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
FR2724935B1 (fr) * 1994-09-27 1996-12-20 Centre Nat Rech Scient Compositions nanoparticulaires contenant des derives nucleotidiques, leur preparation et leur emploi en therapeutique
KR960016882A (ko) * 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
EP0805678B1 (fr) * 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Nanoparticules a modification de surface et leurs procedes de fabrication et d'utilisation

Also Published As

Publication number Publication date
AU720989B2 (en) 2000-06-22
AU3454697A (en) 1998-02-02
GB2330534A (en) 1999-04-28
EP0986404A2 (fr) 2000-03-22
DE69712110D1 (de) 2002-05-23
CA2257408A1 (fr) 1998-01-15
NO990003L (no) 1999-01-04
ES2175433T3 (es) 2002-11-16
GB9900054D0 (en) 1999-02-24
EP0994726A2 (fr) 2000-04-26
JP2000514086A (ja) 2000-10-24
EP0994726B1 (fr) 2002-04-17
DK0986404T3 (da) 2002-05-13
DE69712108T2 (de) 2002-12-12
WO1998001161A3 (fr) 1998-03-12
WO1998001160A2 (fr) 1998-01-15
PT994726E (pt) 2002-09-30
JP2001500109A (ja) 2001-01-09
AU726518B2 (en) 2000-11-09
ATE216265T1 (de) 2002-05-15
KR20000023716A (ko) 2000-04-25
AU3454597A (en) 1998-02-02
CA2257300A1 (fr) 1998-01-15
ES2175434T3 (es) 2002-11-16
DE69712110T2 (de) 2002-12-12
KR20000067855A (ko) 2000-11-25
AU726518C (en) 2002-01-03
NO990002D0 (no) 1999-01-04
WO1998001160A3 (fr) 1998-03-05
WO1998001161A2 (fr) 1998-01-15
GB2330534B (en) 2000-09-06
GB2330532A (en) 1999-04-28
GB9900048D0 (en) 1999-02-24
ATE216264T1 (de) 2002-05-15
PT986404E (pt) 2002-09-30
DE69712108D1 (de) 2002-05-23
NO990002L (no) 1999-01-04
EP0986404B1 (fr) 2002-04-17

Similar Documents

Publication Publication Date Title
NO990003D0 (no) Administreringssystem for genterapi
IL133162A0 (en) Device and methods for wound treatment
EP1650293A4 (fr) Cellule magnetique et utilisation
ES2243229T3 (es) Formulaciones de particulas de hidrogel.
IL132156A0 (en) Neoglycoproteins
ATE182175T1 (de) Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität
BR9703417A (pt) Processo para a fabricação de um suplemento de reção animal sobre base de caldo de fermentação
EP0900569A3 (fr) Médicament destiné au traitement d'un disque intervertébral blessé par hernie
PT868505E (pt) Inducao condrogenica in vitro de celulas estaminais mesenquimais humanas
BG106106A (en) Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma
GR3033534T3 (en) Genetic therapy of diseases of the central nervous system with a cell-specific active substance which is dependent on the cell cycle
FR2763943B1 (fr) Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
CA2315115A1 (fr) Compositions a base de microspheres destinees au traitement des blessures
BR9305783A (pt) Processo para preparar grânulos dispersiveis em água e grânulos dispersíveis em água
CA2377373A1 (fr) Donneurs d'oxyde nitrique induisant la neurogenese
AR016312A1 (es) USO DE UN COMPUESTO DE MEJORAMIENTO DE LA ADINISTRACIoN DE AGENTES TERAPÉUTICOS, COMPOSICIONES FARMACÉUTICAS Y DICHO COMPUESTO.
IT8921243A0 (it) Nuovi geni ibridi funzionali di bacillus thuringiensis ottenuti mediante ricombinazione in vivo.
IL141486A0 (en) Pharmaceutical compositions containing a cd2 binding agent
EP1005324A4 (fr) Compositions diffusant des agents biologiques et leurs procedes de preparation
IL149004A0 (en) Magnetic targeted carrier composed of iron and porous materials for the targeted delivery of biologically active agents
JP2002503671A5 (fr)
NZ318272A (en) Glucocorticoid enhancement of gene expression
鲁林荣 et al. Enhancing expression of APEX gene by IL-2 in mouse T cells
Quintavalla et al. Differential induction of stromelysin mRNA by bovine articular chondrocytes treated with interferon‐γ and interleukin‐1α
Von Bonin et al. Therapy of acute graft-versus-host disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application